Drug intelligence / Profile preview

AntiCov-220

Development stage: Phase 4

Overview

AntiCov-220 is a named investigational multi-herb and nutrient mixture evaluated in a completed Phase 4 ClinicalTrials.gov study, NCT05043324, for prevention and treatment of COVID-19 before, during, and after SARS-CoV-2 infection. The registered study describes a composition containing ascorbic acid, L-arginine hydrochloride, extracts of Adenosma glutinosum, Eclipta prostrata, Phyllanthus urinaria, and Impatiens balsamina, rutin, pregnenolone acetate, Allium sativum, pyridoxine 5-phosphate, and cyanocobalamin. Its proposed antiviral, anti-inflammatory, cell-protective, and immune-supporting effects are claims in the trial registry; no specific molecular target or independently established mechanism of action was identified.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on AntiCov-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AntiCov-220.

Explore the full profile